|
|
Flagellin |
|
Vaxjo ID |
85 |
|
Vaccine Adjuvant Name |
Flagellin |
|
Alternative Names |
FliC |
|
Adjuvant VO ID |
VO_0001331
|
|
Description |
Flagellin from gram-negative bacteria is used as an adjuvant and is a TLR5 agonist. Flagellin is a protein that aligns to form a hollow cylinder as part of a bacteria's flagellum. |
|
Stage of Development |
Clinical Trial |
|
Components |
Flagellin protein |
|
Function |
Gram-negative flagellin, a Toll-like receptor 5 (TLR5) agonist, is a potent inducer of innate immune effectors such as cytokines and nitric oxide (Honko et al., 2006). The plasticity of flagellin has allowed for the generation of a range of flagellin–Ag fusion proteins that have proven to be effective vaccines in animal models (Mizel and Bates, 2010). |
|
Safety |
Flagellin has no detectable toxicity in rabbits when given intranasally (i.n.) or i.m. using a two-dose protocol (100–500 μg) over 28 days (Mizel and Bates, 2010). |
| Related Vaccine(s) |
|
| References |
Honko et al., 2006: Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infection and immunity. 2006; 74(2); 1113-1120. [PubMed: 16428759].
Mizel and Bates, 2010: Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. Journal of immunology (Baltimore, Md. : 1950). 2010; 185(10); 5677-5682. [PubMed: 21048152].
|
|
